Emerging DDT Report

Emerging Drug Delivery Technologies:
Profiles of Start-Ups and Early Stage Companies

Publication Date: May 2013

 

Report Summary

MCD Group continuously researches and monitors emerging drug delivery technologies and has compiled this report to profile some of the innovative developments at younger, emerging companies. The report focuses on start-ups and smaller companies that tend to be less well known, but are expected to gain momentum as they advance their technologies and produce significant clinical data. All of the companies profiled have interest in forming new partnerships or receiving funding to enable further development and eventual commercialization of their technologies.

The report features profiles of 62 companies, a majority of which were founded in the past five years. Most are located in the United States; however a few profiled companies are based in Canada, Europe, and Australia. Approximately 50% of the companies are affiliated with a University, and ten companies have initiated human clinical trials.

Collectively, the emerging companies profiled in this report are focused on 11 different therapeutic categories. Oncology is the leading focus among companies investigated, and approximately 25 percent of the companies profiled are developing proprietary technologies designed to improve delivery of macromolecules/biologics. Another 25 percent of the companies are focused on novel delivery devices, ranging from inhalation and nasal devices, to more patient-friendly injectable systems. All of the companies investigated are developing technologies that could potentially transform drug delivery in one or more therapeutic areas.

For each company profiled, the following information is provided:

• Detailed Technology Description
• Development Status / Pipeline Products
• Patents and Publications
• Partnership and Funding Opportunities
• Company background (date founded, affiliations)
• Business Development & Licensing Contact

Examples of Technologies Presented:

• Mini-pump for subcutaneous delivery of IV medications
• Targeted nanoparticle micelles
• Antibody-targeted liposomes
• Abuse-deterrent delivery system
• Dry powder particle processing technology
• Oral capsule technology for biologics
• Nanovesicle delivery system for delivery across the BBB
• Timed-release intra-ocular implant device
• Non-invasive aerosol device for brain drug delivery
• Extracellular drug conjugate technology
• Nanoparticles and novel device for CNS and inner ear drug delivery
• Next-generation auto-injector technology
• Nanopolymer drug conjugates
• Microneedle patch system
• Pocket-sized ultrasound delivery device
• Biodegradable, topical drug patch

Sample of Companies Profiled:

Aquarius Biotechnologies
Lauren Sciences
Convoy Therapeutics
Orbis Biosciences
Corinthian Ophthalmic
Qrono, Inc.
Entrega, Inc.
scPharmaceuticals
HylaPharm
TheraTarget
Inspiro Medical
ZetrOZ, LLC

Reasons to Buy:

• Identify early stage delivery technologies that will potentially “enable” the _delivery _of your therapeutic compound

• Learn about investment opportunities with emerging companies, to gain _.access _.to promising, early stage technologies

.Identify novel drug delivery formulations available for partnering, to _.enhance your _product portfolio

Price: $1,995.00 PDF single-copy
ORDER REPORT

©2009. MCD GROUP, LLC. All Rights Reserved. Website Designed & Maintained by SHDOW, LLC